Analisi costi-efficacia di 90Y-ibritumomab tiuxetano (Zevalin®) vs. terapie attualmente disponibili nel trattamento dei pazienti affetti da Linfoma Non-Hodgkin (LNH) refrattario o recidivato

Analisi costi-efficacia di 90Y-ibritumomab tiuxetano (Zevalin®) vs. terapie attualmente disponibili nel trattamento dei pazienti affetti da Linfoma Non-Hodgkin (LNH) refrattario o recidivato

The aim of the paper is to compare Italian healthcare-related costs and effectiveness of 90Y-ibritumomab tiuxetan (Zevalin®) vs. currently available II and III line therapies (chemotherapy; radiotherapy; stem cell transplant) for relapsing or refractory Non-Hodgkin Lymphoma (NHL). A cost-effectivene...

Full description

Bibliographic Details
Main Authors: Carlo Lazzaro, Manolo Beelke
Format: Article
Language:English
Published: SEEd Medical Publishers 2005-12-01
Series:Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:
relapsing or refractory non-hodgkin lymphoma
90y-ibritumomab tiuxetan
ii and iii line therapies
cost-effectiveness analysis
Online Access:https://journals.seedmedicalpublishers.com/index.php/FE/article/view/845

Similar Items

Similar Items